Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Palatin Technologies, Inc. Common Stock

PTN

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $5.21 – $6.26
Volume 46,622
Market cap $11M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.92M
Price / earnings
—
Price / book
1.63×
Price / sales
0.83×
EV / sales
0.26×
EV / EBITDA
-0.4×

Profitability

Earnings per share
-$4.70
Return on assets
-98.29%
Return on equity
-125.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.61×
Quick ratio
4.61×
Cash ratio
4.23×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PTN, quarterly periods
Line itemQ4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024Q1 FY2025 Sep 30, 2024
Revenue$300.77K$3.92M$116.04K$8.85M$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$300.77K$3.92M$116.04K$8.85M$0$0$0$0
Selling, general and administrative$2.71M$1.98M$3.12M$1.66M$2.63M$1.47M$1.68M$2.02M
Research and development$2.01M$3.52M$4.32M$2.53M$1.97M$3.76M$3.43M$5.74M
Total operating expenses$4.72M$5.5M$7.44M$4.19M$2.9M$4.81M$5.11M$7.76M
Operating income-$4.42M-$1.58M-$7.33M$4.66M-$2.9M-$4.81M-$5.11M-$7.76M
Interest expense-$2.96K-$1.27K-$498-$2K-$3.49K-$1.8K-$3.8K-$5.94K
Income before taxes-$4.36M-$1.43M-$7.26M$4.68M-$2.23M-$4.81M-$2.44M-$7.82M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.36M-$1.43M-$7.26M$4.68M-$2.23M-$4.81M-$2.44M-$7.82M
Net income attributable to common shareholders-$4.36M-$1.43M-$7.26M$4.68M-$2.23M-$4.81M-$2.44M-$7.82M
EBITDA-$4.4M-$1.56M-$7.31M$4.68M-$2.85M-$4.76M-$5.04M-$7.68M
Basic earnings per share-$1.12-$0.37-$2.86$4.81-$2.73-$9.13-$5.92-$19.71
Diluted earnings per share-$1.16-$0.37-$2.86$4.26-$2.73-$9.13-$5.92-$19.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 31, 20221-for-25reverse split
Sep 27, 20101-for-10reverse split